ZBH Stock Price & Latest News
Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers. Zimmer Biomet’s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Centre Asset Management LLC (0.04%), Thomasville National Bank (0.04%), Brookstone Capital Management (0.02%), Jacobs & Co. CA (0.02%), DnB Asset Management AS (0.02%) and DNB Asset Management AS (0.02%).
For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.
Zacks Research is Reported On:
Insiders that own company stock include Arthur J Higgins, Chad F Phipps, Sang Yi and Zuilen Wilfred Van. Zimmer Biomet issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of $7.40-$7.50 for the period, compared to the consensus estimate of $7.06.
Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. All investments involve the risk of loss and https://g-markets.net/helpful-articles/bull-flag-chart-pattern/ the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.
In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders. According to 19 analysts, the average rating for ZBH stock is “Hold.” The 12-month stock price forecast is $137.64, which is a decrease of -3.32% from the latest price. Some of the biggest medical device companies’ stocks have dropped to attractive prices due to the current COVID-19 pandemic.
- “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).
- New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions.
- The monthly returns are then compounded to arrive at the annual return.
In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet’s products. Over the past few years, Zimmer Biomet has reported steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level.
Invest in Zimmer Biomet (zbh)
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
Syneos Health’s (SYNH) share price movement is expected to be favorable due to the strength of the company’s Syneos One portfolio and several value-added partnership deals. Get this delivered to your inbox, and more info about our products and services. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
15 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” ZBH shares.
Zimmer Biomet Announces Third Quarter 2022 Financial Results
Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System.
MarketBeat’s analysts have just released their top five short plays for July 2023. Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants. To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development. Zimmer Biomet is expanding its product portfolio through innovation and acquisitions.
Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017.
Zimmer Biomet to Present at Bank of America Securities and Jefferies Healthcare Conferences
The “Halftime Report” traders give their top picks to watch for the second half. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter. New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions. As elective surgery candidates return to operating rooms, revenue will ramp up. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
Shareholders of record on Monday, June 26th will be paid a dividend of $0.24 per share on Monday, July 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.67%. The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products. For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. The company’s hip and knee replacement products continue to enjoy solid demand.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.